Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
4Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Capricor Therapeutics, Inc. (CAPR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
4Distinct source URLs
7High confidence
0.793Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Capricor Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
NIPPON-SHINYAKU-CO-LTD
NIPPON-SHINYAKU-CO-LTD
92%
The Lawsuit alleges a fundamental pricing flaw in the Commercialization and Distribution Agreement dated January 24, 2022, between the Company and Nippon Shinyaku Co., Ltd. (the “U.S. Distribution Ag…
NS-PHARMA
NS-PHARMA
92%
The Lawsuit also seeks relief from Nippon Shinyaku Co. Ltd.’s U.S. subsidiary, NS Pharma (collectively “NS”).
CEDARS-SINAI-MEDICAL-CENTER
CEDARS-SINAI-MEDICAL-CENTER
90%
The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor
NIPPON-SHINYAKU
NIPPON-SHINYAKU
90%
The Company has evaluated the Japan Distribution Agreement in accordance with ASC 606, Revenue for Contracts from Customers.
RNA
Atrium Therapeutics, Inc.
72%
Reciprocal relationship from RNA graph: Reciprocal relationship from CAPR graph: Reciprocal relationship from RNA graph: ss of our products, as well as the cost of treatment with our products in rela…
Reciprocal relationship from SRPT graph: Reciprocal relationship from CAPR graph: be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be res…
be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to withdraw from a clinical trial as a resul…
Reciprocal relationship from YDES graph: Reciprocal relationship from CAPR graph: Reciprocal relationship from YDES graph: ontributed approximately 53.7% of the Company’s total revenue. For the year …
be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to withdraw from a clinical trial as a resul…
Reciprocal relationship from SRPT graph: Reciprocal relationship from CAPR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from CAPR graph: Reciprocal relationship from SRPT g…
NS-PHARMA-INC
NS-PHARMA-INC
62%
of which may already be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to withdraw from a clin…
SECURITIES-INVESTOR-PROTECTION-CORPORATION
SECURITIES-INVESTOR-PROTECTION-CORPORATION
62%
n the consolidated balance sheet, are now presented separately. Provision for income taxes, which was previously included in general and administrative expenses, has been reclassified and is now pres…
Capricor Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CAPR-DEBT
Debt stack $14.8M
90%
Market cache reports total debt of $14.8M.
CAPR-DEBT-8474
Warrants outstanding: 4.01
90%
xbrl warrant detail from xbrl 2021-12-31.
Capricor Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Capricor Therapeutics, Inc..
Capricor Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CAPR-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 181 tracked holders.
Capricor Therapeutics, Inc. Extended Supply Chain Network
